BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 38548420)

  • 1. Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
    Carter TC; Medina-Flores R; Lawler BE
    Biomed Res Int; 2018; 2018():6204676. PubMed ID: 30687753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Targeting of Transcription and Metabolism in Glioblastoma.
    Su YT; Chen R; Wang H; Song H; Zhang Q; Chen LY; Lappin H; Vasconcelos G; Lita A; Maric D; Li A; Celiku O; Zhang W; Meetze K; Estok T; Larion M; Abu-Asab M; Zhuang Z; Yang C; Gilbert MR; Wu J
    Clin Cancer Res; 2018 Mar; 24(5):1124-1137. PubMed ID: 29254993
    [No Abstract]   [Full Text] [Related]  

  • 3. Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma.
    Surendran A; Jenner AL; Karimi E; Fiset B; Quail DF; Walsh LA; Craig M
    J Pharmacol Exp Ther; 2023 Oct; 387(1):66-77. PubMed ID: 37442619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma.
    Saha D; Rabkin SD; Martuza RL
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward more accurate preclinical glioblastoma modeling: Reverse translation of clinical standard of care in a glioblastoma mouse model.
    Ziani-Zeryouh A; Wouters R; Thirion G; Vandenbrande K; Vankerckhoven A; Berckmans Y; Bevers S; Verbeeck J; De Keersmaecker K; Coosemans A; Riva M
    Methods Cell Biol; 2024; 183():381-397. PubMed ID: 38548420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide for immunomodulation in the treatment of glioblastoma.
    Karachi A; Dastmalchi F; Mitchell DA; Rahman M
    Neuro Oncol; 2018 Nov; 20(12):1566-1572. PubMed ID: 29733389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide for high grade glioma.
    Hart MG; Garside R; Rogers G; Stein K; Grant R
    Cochrane Database Syst Rev; 2013 Apr; 2013(4):CD007415. PubMed ID: 23633341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.
    McBain C; Lawrie TA; Rogozińska E; Kernohan A; Robinson T; Jefferies S
    Cochrane Database Syst Rev; 2021 May; 5(1):CD013579. PubMed ID: 34559423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme.
    Aldoghachi AF; Aldoghachi AF; Breyne K; Ling KH; Cheah PS
    Neuroscience; 2022 May; 491():240-270. PubMed ID: 35395355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.
    Jiapaer S; Furuta T; Tanaka S; Kitabayashi T; Nakada M
    Neurol Med Chir (Tokyo); 2018 Oct; 58(10):405-421. PubMed ID: 30249919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.